The values for likelihood to achieve NEDA than experience any AE ratio (LHH (AE/NEDA) ) were 3.9, 6.8, 12.5 and 3.7, the likelihood to achieve NEDA than experience a SAE ratio (LHH (SAE/NEDA) ) values were 3.5, 15, 23.5 and 2.8, and the likelihood to achieve NEDA versus discontinue treatment (LHH (AE-D/NEDA) ) values were 20.3, 4.3, 3.9 and 3.1 for cladribine, dimethyl-fumarate, fingolimod, and teriflunomide, respectively.
The NNTH AE values were 15 (95% CI 7.8 to 65.2) for cladribine, 52 (95% CI 23.6 to − 270.1) for DMF, 68 (95% CI 27.7 to − 153.1) for fingolimod, and 44 (95% CI 14.6 to − 44.2) for teriflunomide, indicating that fingolimod has the most and cladribine the least favorable safety profile with regard to the appearance of any AE (Table 4) .
Should read:
The NNTH AE values were 14 (95% CI 7.7 to 56.2) for cladribine, 52 (95% CI 23.6 to − 270.1) for DMF, 68 (95% CI 27.7 to − 153.1) for fingolimod, and 31 (95% CI 12.8 to − 79.2) for teriflunomide, indicating that fingolimod has the most and cladribine the least favorable safety profile with regard to the appearance of any AE (Table 4 ).
The original article can be found online at https ://doi.org/10.1007/ s4026 3-018-0547-z. AR attributable risk (proportion of patients achieving NEDA in active group minus proportion of patients achieving NEDA in placebo group), CI confidence interval, NEDA no evidence of disease activity, NNTB NEDA number of patients needed to treat for a patient to achieve NEDA, RR relative risk (proportion of patients achieving NEDA in active group out of the total patients in the active group over the proportion of patients achieving NEDA in placebo group out of the total patients in placebo group)
Should read: AR attributable risk (proportion of patients achieving NEDA in active group minus proportion of patients achieving NEDA in placebo group), CI confidence interval, NEDA no evidence of disease activity, NNTB NEDA number of patients needed to treat for a patient to achieve NEDA, RR relative risk (proportion of patients achieving NEDA in active group out of the total patients in the active group over the proportion of patients achieving NEDA in placebo group out of the total patients in placebo group) Table 4 that read: AE adverse event, AE-D adverse event leading to treatment discontinuation, CI confidence interval, DMF dimethyl-fumarate, NNTB number of patients needed to treat for a patient to have a good outcome (to achieve no evidence of activity), NNTH number of patients needed to treat for a patient to have a harmful outcome, SAE serious adverse event. In some cases the harmful effect of the treatment leading to an AE was not significantly different from placebo at the p 0.05 level and resulted in the 95% CIs of the NNTH to include infinity (∞) a No significant difference between active treatment and placebo AE adverse event, AE-D adverse event leading to treatment discontinuation, CI confidence interval, DMF dimethyl-fumarate, NNTB number of patients needed to treat for a patient to have a good outcome (to achieve no evidence of activity), NNTH number of patients needed to treat for a patient to have a harmful outcome, SAE serious adverse event. In some cases the harmful effect of the treatment leading to an AE was not significantly different from placebo at the p 0.05 level and resulted in the 95% CIs of the NNTH to include infinity (∞) a No significant difference between active treatment and placebo
